Molecular Predictors in GlioblastomaToward Personalized Therapy
Howard Colman, MD, PhD;
Ken Aldape, MD
Arch Neurol. 2008;65(7):877-883.
Recent therapeutic advances have improved standard treatment for patients with newly diagnosed glioblastoma. Unfortunately, even with these improvements, only a fraction of patients derive significant benefit and experience prolonged survival. These findings are consistent with long-standing clinical and recent molecular evidence that subtypes of glioblastoma exist with differing survival rates and response to treatment. However, patients with newly diagnosed glioblastoma are currently treated in a uniform fashion, without regard for potential underlying differences in molecular alterations or prognosis. In this review, we will discuss recent progress toward the identification of robust and clinically relevant molecular subgroups of glioblastoma and initial steps in using this information to individualize therapy and overcome treatment resistance.
Author Affiliations: Departments of Neuro-oncology (Dr Colman) and Pathology (Dr Aldape), and Brain Tumor Center (Drs Colman and Aldape), University of Texas M. D. Anderson Cancer Center, Houston.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Neurology
Arch Neurol. 2008;65(7):871-872.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas
de Tayrac et al.
Clin. Cancer Res. 2011;17:317-327.
ABSTRACT
| FULL TEXT
Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 Genes Involved in the Double-Strand Break Repair Pathway Predict Glioblastoma Survival
Liu et al.
JCO 2010;28:2467-2474.
ABSTRACT
| FULL TEXT
|
